Author

Alessandra Oortwijn 1

1 Galapagos NV,Leiden,Netherlands

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire, Alessandra Oortwijn, Simon Hatch, Silvio Danese, Toshifumi Hibi, Brian Feagan, William J. Sandborn

CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POST HOC ANALYSIS OF SELECTION

Silvio Danese, Laurent Peyrin-Biroulet, William J. Sandborn, Virginia Taliadouros, Alessandra Oortwijn, Stefan Schreiber, Ken Hasegawa, Javaria Mona Khalid, Robin Besuyen

CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS

Sander Strengholt, Peter C. Taylor, Christina Charles-Schoeman, Muhsen Alani, Mona Trivedi, Vanessa Castellano, Iyabode Tiamiyu, Deyuan Jiang, Lei Ye, Michael Nurmohamed, Gerd Burmester, Alessandra Oortwijn

CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS

Alessandra Oortwijn

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Marc Ferrante, Alessandra Oortwijn, Chohee Yun, Jie Zhang, Laurent Peyrin-Biroulet, Severine Vermeire, Silvio Danese, Brian Feagan

EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL

Laurent Peyrin-Biroulet, Iris Dotan, Alessandra Oortwijn, Brian Feagan, Toshifumi Hibi, Virginia Taliadouros, Sally Zhao, Jie Zhang, Jeremy Hsieh

Item 1 - 6 / 6
1